A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of HS-10511 in Healthy Subjects
Latest Information Update: 25 Jan 2024
At a glance
- Drugs HS 10511 (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 25 Jan 2024 New trial record